Literature DB >> 21827434

Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Mark R Schleiss1.   

Abstract

Human cytomegalovirus (CMV) is responsible for approximately 40,000 congenital infections in the United States each year. Congenital CMV disease frequently produces serious neurodevelopmental disability, as well as vision impairment and sensorineural hearing loss. Development of a CMV vaccine is therefore considered to be a major public health priority. The mechanisms by which CMV injures the fetus are complex and likely include a combination of direct fetal injury induced by pathologic virally-encoded gene products, an inability of the maternal immune response to control infection, and the direct impact of infection on placental function. CMV encodes gene products that function, both at the RNA and the protein level, to interfere with many cellular processes. These include gene products that modify the cell cycle; interfere with apoptosis; induce an inflammatory response; mediate vascular injury; induce site-specific breakage of chromosomes; promote oncogenesis; dysregulate cellular proliferation; and facilitate evasion of host immune responses. This minireview summarizes current concepts regarding these aspects of the molecular virology of CMV and the potential pathogenic impact of viral gene expression on the developing fetus. Areas for potential development of novel therapeutic intervention are suggested for improving the outcome of this disabling congenital infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827434      PMCID: PMC3869401          DOI: 10.2174/187152611797636721

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  190 in total

Review 1.  Cloning of herpesviral genomes as bacterial artificial chromosomes.

Authors:  Heiko Adler; Martin Messerle; Ulrich H Koszinowski
Journal:  Rev Med Virol       Date:  2003 Mar-Apr       Impact factor: 6.989

Review 2.  Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns.

Authors:  Mark R Schleiss
Journal:  ILAR J       Date:  2006

3.  Inhibition of calmodulin-dependent kinase kinase blocks human cytomegalovirus-induced glycolytic activation and severely attenuates production of viral progeny.

Authors:  Jessica McArdle; Xenia L Schafer; Joshua Munger
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

4.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.

Authors:  S B Boppana; L B Rivera; K B Fowler; M Mach; W J Britt
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

5.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa.

Authors:  J D Eudy; M D Weston; S Yao; D M Hoover; H L Rehm; M Ma-Edmonds; D Yan; I Ahmad; J J Cheng; C Ayuso; C Cremers; S Davenport; C Moller; C B Talmadge; K W Beisel; M Tamayo; C C Morton; A Swaroop; W J Kimberling; J Sumegi
Journal:  Science       Date:  1998-06-12       Impact factor: 47.728

Review 7.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

8.  A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling.

Authors:  Christina Paulus; Steffen Krauss; Michael Nevels
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-23       Impact factor: 11.205

9.  Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.

Authors:  Jeremy P Kamil; Adam J Hume; Igor Jurak; Karl Münger; Robert F Kalejta; Donald M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-15       Impact factor: 11.205

10.  Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors.

Authors:  M Mendelson; S Monard; P Sissons; J Sinclair
Journal:  J Gen Virol       Date:  1996-12       Impact factor: 3.891

View more
  18 in total

1.  CMV-induced embryonic mouse organ of corti dysplasia: Network architecture of dysfunctional lateral inhibition.

Authors:  Michael Melnick; Tina Jaskoll
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-07-14

2.  Mother-to-Child Transmission of Cytomegalovirus and Prevention of Congenital Infection.

Authors:  Robert F Pass; Brenna Anderson
Journal:  J Pediatric Infect Dis Soc       Date:  2014-09       Impact factor: 3.164

3.  Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors:  Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2015-06-13       Impact factor: 3.641

4.  A role for 3-O-sulfated heparan sulfate in promoting human cytomegalovirus infection in human iris cells.

Authors:  John Baldwin; Erika Maus; Brian Zanotti; Michael V Volin; Ritesh Tandon; Deepak Shukla; Vaibhav Tiwari
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

5.  Cytomegalovirus Seropositivity as a Potential Risk Factor for Increased Noise Trauma Susceptibility.

Authors:  Moritz Groschel; Stefan Voigt; Susanne Schwitzer; Arne Ernst; Dietmar Basta
Journal:  Noise Health       Date:  2022 Jan-Mar       Impact factor: 1.293

6.  Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Authors:  Mark R Schleiss; K Yeon Choi; Jodi Anderson; Janine Gessner Mash; Martine Wettendorff; Sally Mossman; Marc Van Damme
Journal:  Vaccine       Date:  2013-07-16       Impact factor: 3.641

Review 7.  Asymptomatic DNAemia heralds CMV-associated NEC: case report, review, and rationale for preemption.

Authors:  Supatida Tengsupakul; Nicole D Birge; Catherine M Bendel; Robyn C Reed; Beth-Ann Bloom; Nelmary Hernandez; Mark R Schleiss
Journal:  Pediatrics       Date:  2013-10-21       Impact factor: 7.124

Review 8.  Cytomegalovirus in the neonate: immune correlates of infection and protection.

Authors:  Mark R Schleiss
Journal:  Clin Dev Immunol       Date:  2013-08-19

Review 9.  Renal Involvement in Congenital Cytomegalovirus Infection: A Systematic Review.

Authors:  María Ríos-Barnés; Clàudia Fortuny; Ana Alarcón; Antoni Noguera-Julian
Journal:  Microorganisms       Date:  2021-06-15

Review 10.  Prenatal cytomegalovirus, rubella, and Zika virus infections associated with developmental disabilities: past, present, and future.

Authors:  Eliza Gordon-Lipkin; Alexander Hoon; Carlos A Pardo
Journal:  Dev Med Child Neurol       Date:  2020-10-21       Impact factor: 4.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.